⁸⁹Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.

ABSTRACT: The hepatocyte growth factor (HGF) binding antibody rilotumumab (AMG102) was modified for use as a ⁸⁹Zr-based immuno-PET imaging agent to noninvasively determine the local levels of HGF protein in tumors. Because recent clinical trials of HGF-targeting therapies have been largely unsuccessful in several different cancers (e.g., gastric, brain, lung), we have synthesized and validated ⁸⁹Zr-DFO-AMG102 as a companion diagnostic for improved identification and selection of patients having high local levels of HGF in tumors. To date, patient selection has not been performed using the local levels of HGF protein in tumors. Methods: The chelator p-SCN-Bn-DFO was conjugated to AMG102, radiolabeling with ⁸⁹Zr was performed in high radiochemical yields

SUBMITTER: Price EW 

PROVIDER: S-EPMC5577625 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature